Literature DB >> 17275009

Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification.

R de Vries1, A K Groen, F G Perton, G M Dallinga-Thie, M J A van Wijland, L D Dikkeschei, B H R Wolffenbuttel, A van Tol, R P F Dullaart.   

Abstract

We tested whether hypertriglyceridemia associated with type 2 diabetes mellitus is accompanied by alterations in pre beta-HDL, which are considered to be initial acceptors of cell-derived cholesterol, and by changes in the ability of plasma to promote cellular cholesterol efflux. In 28 hypertriglyceridemic and 56 normotriglyceridemic type 2 diabetic patients, and in 56 control subjects, we determined plasma lipids, HDL cholesterol and phospholipids, plasma pre beta-HDL and pre beta-HDL formation, phospholipid transfer protein (PLTP) activity, plasma cholesterol esterification (EST) and cholesteryl ester transfer (CET) and the ability of plasma to stimulate cholesterol efflux out of cultured human fibroblasts. HDL cholesterol and HDL phospholipids were lower, whereas plasma PLTP activity, EST and CET were higher in hypertriglyceridemic diabetic patients than in the other groups. Pre beta-HDL levels and pre beta-HDL formation were unaltered, although the relative amount of pre beta-HDL (expressed as % of total plasma apo A-I) was increased in hypertriglyeridemic diabetic patients. Cellular cholesterol efflux to plasma from hypertriglyceridemic diabetic patients was increased compared to efflux to normotriglyceridemic diabetic and control plasma, but efflux to normotriglyceridemic diabetic and control plasma did not differ. Multiple linear regression analysis demonstrated that cellular cholesterol efflux to plasma was positively and independently related to pre beta-HDL formation, PLTP activity and EST (multiple r=0.48), but not to the diabetic state. In conclusion, cholesterol efflux from fibroblasts to normotriglyceridemic diabetic plasma is unchanged. Efflux to hypertriglyceridemic diabetic plasma is enhanced, in association with increased plasma PLTP activity and cholesterol esterification. Unaltered pre beta-HDL formation in diabetic hypertriglyceridemia, despite low apo A-I, could contribute to maintenance of cholesterol efflux.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17275009     DOI: 10.1016/j.atherosclerosis.2006.12.027

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  23 in total

Review 1.  Derangements of intravascular remodeling of lipoproteins in type 2 diabetes mellitus: consequences for atherosclerosis development.

Authors:  Geesje M Dallinga-Thie; Robin P F Dullaart; Arie van Tol
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

Review 2.  Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism.

Authors:  John J Albers; Simona Vuletic; Marian C Cheung
Journal:  Biochim Biophys Acta       Date:  2011-06-28

3.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

Authors:  Amit V Khera; Marina Cuchel; Margarita de la Llera-Moya; Amrith Rodrigues; Megan F Burke; Kashif Jafri; Benjamin C French; Julie A Phillips; Megan L Mucksavage; Robert L Wilensky; Emile R Mohler; George H Rothblat; Daniel J Rader
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

Review 4.  High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity.

Authors:  Anand Rohatgi
Journal:  Prog Cardiovasc Dis       Date:  2015-05-09       Impact factor: 8.194

5.  Plasma lipids, lipoprotein metabolism and HDL lipid transfers are equally altered in metabolic syndrome and in type 2 diabetes.

Authors:  Vanessa M Silva; Carmen G C Vinagre; Luis A O Dallan; Ana P M Chacra; Raul C Maranhão
Journal:  Lipids       Date:  2014-04-10       Impact factor: 1.880

6.  Glycoxidized HDL, HDL enriched with oxidized phospholipids and HDL from diabetic patients inhibit platelet function.

Authors:  Quang Huy Lê; Meddy El Alaoui; Evelyne Véricel; Bérénice Ségrestin; Laurent Soulère; Michel Guichardant; Michel Lagarde; Philippe Moulin; Catherine Calzada
Journal:  J Clin Endocrinol Metab       Date:  2015-03-20       Impact factor: 5.958

7.  Elevated baseline plasma phospholipid protein (PLTP) levels are an independent predictor of long-term all-cause mortality in patients with diabetes mellitus and known or suspected coronary artery disease.

Authors:  Erdal Cavusoglu; Jonathan D Marmur; Sandeep Chhabra; Mohammad R Hojjati; Sunitha Yanamadala; Vineet Chopra; Calvin Eng; Xian-Cheng Jiang
Journal:  Atherosclerosis       Date:  2015-02-16       Impact factor: 5.162

8.  Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks.

Authors:  Xin-Min Li; Wai Hong Wilson Tang; Marian K Mosior; Ying Huang; Yuping Wu; William Matter; Vivian Gao; David Schmitt; Joseph A Didonato; Edward A Fisher; Jonathan D Smith; Stanley L Hazen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-03-21       Impact factor: 8.311

9.  High-density lipoprotein cholesterol efflux capacity is not associated with atherosclerosis and prevalence of cardiovascular outcome: The CODAM study.

Authors:  Tatjana Josefs; Kristiaan Wouters; Uwe J F Tietge; Wijtske Annema; Robin P F Dullaart; Tomas Vaisar; Ilja C W Arts; Carla J H van der Kallen; Coen D A Stehouwer; Casper G Schalkwijk; Ira J Goldberg; Edward A Fisher; Marleen M J van Greevenbroek
Journal:  J Clin Lipidol       Date:  2019-10-31       Impact factor: 4.766

10.  Cathepsin G degradation of phospholipid transfer protein (PLTP) augments pulmonary inflammation.

Authors:  Anthony Brehm; Patrick Geraghty; Michael Campos; Itsaso Garcia-Arcos; Abdoulaye Jules Dabo; Adam Gaffney; Edward Eden; Xian-Cheng Jiang; Jeanine D'Armiento; Robert Foronjy
Journal:  FASEB J       Date:  2014-02-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.